NCT05741164View on ClinicalTrials.gov

Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

October 22, 2024

Primary Completion Date

December 15, 2026

Study Completion Date

December 15, 2027

Conditions
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast CarcinomaRefractory Triple-Negative Breast CarcinomaUnresectable Triple-Negative Breast Carcinoma
Interventions
PROCEDURE

Biopsy

Undergo tumor biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT scan

BIOLOGICAL

Pembrolizumab

Given IV

DRUG

Propranolol

Given PO

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

14263

RECRUITING

Roswell Park Cancer Institute, Buffalo

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Roswell Park Cancer Institute

OTHER